Navigation Links
Epizyme, Inc. Granted Notice of Allowance of Patent for EPZ-5676
Date:9/3/2013

here: http://www.epizyme.com/about-us/partnerships.asp

About MLL-r

MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). The disease predominantly occurs in two different age ranges, an adult population and a pediatric population. Although both age ranges share a common genetic driver, the adult disease is frequently a secondary leukemia resulting from prior chemotherapy for a different, unrelated cancer, while the pediatric disease is sporadic in nature. According to research published in the journal Blood in December 2002, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. The five-year event-free survival rate in pediatric patients with the most common MLL-r subtype of ALL is approximately 27 percent, as identified in research published in the New England Journal of Medicine in 2004. The total annual incidence of MLL-r in all patients (adult and pediatric, AML and ALL) in major pharmaceutical markets is approximately 4,900 patients, according to a report by Clarion Healthcare commissioned by Epizyme. Patients with MLL-r are routinely diagnosed today with existing tests that are commonly used in clinical settings, and there is high awareness of MLL-r among oncologists.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs,
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme, Inc. to Present at Upcoming Conferences in September
2. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
3. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
4. Epizyme, Inc. Announces Pricing of Initial Public Offering
5. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
7. Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
8. CorMedix Granted Extension of NYSE MKT Listing
9. QRxPharma Granted US Patent On Hybrid Opioids
10. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... (NASDAQ: TECH ) announced today that it ... Simple Plex platform through its Proteins Platform division under ... the previously acquired CyPlex instrument platform from CyVek. ... technology which integrates an innovatively designed microfluidic cartridge with ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... Embryonic Stem Cell Lines for Therapeutic ... ... has,become the first to report, and painstakingly document, the cloning of a,human ... an,adult donor. The study was published online today by the journal "Stem,Cells.", ...
... SAN DIEGO, Jan. 17 Vical Incorporated,(Nasdaq: ... $2.1 million cash payment,from AnGes MG, Inc. for ... Melanoma (AIMM) Phase 3 trial., AnGes is ... under a,previously announced collaborative agreement through a scheduled ...
Cached Medicine Technology:Study Reports Successful Cloning of Human Embryo Using Adult DNA 2Study Reports Successful Cloning of Human Embryo Using Adult DNA 3Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... , FORT WASHINGTON, Pa., Sept. 21 ... by the LACTAID(R) Brand found that 78 percent of African American ... as a way to manage their lactose intolerance. Yet, 48 ... condition keeps them from consuming important nutrients, such as calcium and ...
... , LOS ANGELES, Sept. 21 Aurora Capital ... billion of assets under management, today announced that it has signed ... to acquire its wholly owned subsidiary, Porex Corporation ("Porex" or the ... closing conditions and is expected to close in the fourth quarter ...
... BIRMINGHAM, Ala., Sept. 21 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... proposal (RFP) from the U.S. Department of Health & Human Services ... of critically ill influenza patients under Emergency Use Authorization (EUA). ... minimum and maximum order quantities to be ordered by the government ...
... , , MINNEAPOLIS, Sept. 21 ... and marketer of state-of-the-art cardiac surgery products and services, today ... of the ATS 3f(R) Aortic Bioprosthesis. Based on the ... is a revolutionary next generation stentless pericardial aortic tissue valve ...
... , , VIRGINIA BEACH, Va., Sept. ... city mayor, and Neptune - God of the Sea? The unveiling ... , , A new twist on pin-up ... to 90, recently shed their inhibitions to bare it all (behind strategically ...
... ... potential viewers, will highlight both the DataDeed and Living Will Solutions services on 9/23. ... Preparedness Month. , ... Friedensburg, PA (PRWEB) September 21, 2009 -- Living in Style will feature the highly ...
Cached Medicine News:Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 2Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 4Health News:Aurora Capital to Acquire Porex Corporation, Leader in Porous Plastic Materials Science 2Health News:Aurora Capital to Acquire Porex Corporation, Leader in Porous Plastic Materials Science 3Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 2Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 3Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 4Health News:ATS Medical Announces Implant Milestone for the ATS 3f Aortic Bioprosthesis Achieved at Columbia University Medical Center 2Health News:ATS Medical Announces Implant Milestone for the ATS 3f Aortic Bioprosthesis Achieved at Columbia University Medical Center 3Health News:Wraps Coming Off 'Nearly-Nude' Senior Calendar in Unique Ceremony 2Health News:Wraps Coming Off 'Nearly-Nude' Senior Calendar in Unique Ceremony 3Health News:Wraps Coming Off 'Nearly-Nude' Senior Calendar in Unique Ceremony 4Health News:TV Spotlight on DataDeed and Living Will Solutions 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: